Recent News

Dynavax Reports Feedback From FDA Meeting Regarding HEPLISAV(TM) Biologic License Application

Jun 10, 2013

Dynavax Reports First Quarter 2013 Financial Results

May 6, 2013

Dynavax Names Eddie Gray as Chief  Executive Officer and Member of the Board of Directors
Apr 30, 2013


Dynavax Appoints David Novack as Senior Vice President, Operations and Quality
Mar 21, 2013

Dynavax Reports Fourth Quarter and Year End 2012 Financial Results

March 1, 2013


Dynavax to Present at the Cowen and Company 33rd Annual Healthcare Conference

February 26, 2013

Dynavax Receives FDA Complete Response Letter on HEPLISAV(TM) Biologic License Application
February 25, 2013

Dynavax to Present at the 31st Annual J.P. Morgan Healthcare Conference

December 17, 2012

Dynavax Announces FDA Advisory Committee Meeting Outcome for HEPLISAV(TM)

November 15, 2012

Dynavax Reports Third Quarter 2012 Financial Results

November 1, 2012

Dynavax to Initiate Phase 1 Studies for TLR-9 Agonist for Asthma

October 31, 2012

More...

Clinical-Stage Pipeline

Our clinical-stage pipeline includes product candidates for the prevention and treatment of infectious diseases. More...

Focused on Infectious Diseases

Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product candidates. Our focus is on serious medical needs in the prevention and treatment of infectious diseases.  

Leading Partners

Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline and AstraZeneca, and our funding agreements support our commitment to discover and develop TLR-based products to address serious medical needs.

Integrated European Subsidiary

Rhein Biotech, our European subsidiary, manufactures hepatitis B surface antigen for our lead product, HEPLISAV hepatitis B vaccine. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.